Caelyx in Ovarian Cancer: Prevention and Treatment of Infusion Reactions and Palmar-plantar Erythrodysesthesia (PPE).

Trial Profile

Caelyx in Ovarian Cancer: Prevention and Treatment of Infusion Reactions and Palmar-plantar Erythrodysesthesia (PPE).

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Jun 2014

At a glance

  • Drugs Doxorubicin liposomal (Primary)
  • Indications Ovarian cancer
  • Focus Adverse reactions
  • Sponsors Schering-Plough
  • Most Recent Events

    • 24 Jun 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
    • 24 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Apr 2009 Planned end date changed from 1 Mar 2009 to 1 Apr 2009 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top